Pharma Third-Party Shared Audits (Rephine/Qualifyze) Response & Remediation Guide
Introducing GxP shared audit models by Rephine and Qualifyze, mapping checklists (EU GMP Part II), common critical findings, and CAPA closure.
Rephine, Qualifyze, and Rx-360 conduct GxP shared audits on API/excipient sites globally, aligned with ICH Q7 / EU GMP Part II. The audit report is added to their registry for drug manufacturers to license. Readiness work should address cleanroom smoke studies, computerized data integrity, and cross-contamination prevention.
Typical Finding Areas in Shared Audits
Historical data shows third-party auditors dive deeper into system integrity compared to standard buyers. Critical/Major findings are often associated with the following areas.
- Cleaning Validation: failing to evaluate residue limits using ADE/PDE for the most active compounds
- Data Integrity: audit trails disabled on HPLC software or lacking documented review records
- HVAC & Water: uncalibrated dust sensors, or pressure differential logs missing verification signatures
FAQ
How long is a shared audit report valid?+
A shared audit report is typically valid for 3 years. When a pharma buyer sources from you, they license the report directly. If findings exist, the buyer requires the site to submit a CAPA tracker and closure evidence.
Next steps
If this topic applies to your product, facility, or supply chain requirement, start by confirming the target market, customer-required standard, existing documents, audit history, and expected timeline.
